文献速递临床试验与 GCP

口服甲泼尼龙对IgA肾病患者肾功能下降或肾衰竭的影响:TESTING随机临床试验

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

TESTING国际多中心双盲随机试验纳入503例高危进展的IgA肾病患者,比较口服甲泼尼龙与安慰剂。在中位4.2年随访中,甲泼尼龙组主要复合终点(eGFR下降40%、肾衰竭或肾病死亡)发生率为28.8%,安慰剂组为43.1%(HR 0.53,95%CI 0.39-0.72,P<.001)。甲泼尼龙显著降低主要终点风险,但严重不良事件更常见,主要见于全剂量治疗。

要点

  • 口服甲泼尼龙6-9个月较安慰剂显著降低肾功能下降、肾衰竭或肾病死亡复合终点风险(HR 0.53)。
  • 肾衰竭发生率甲泼尼龙组19.5% vs 安慰剂组27.2%(HR 0.59),差异显著。
  • 严重不良事件甲泼尼龙组10.9% vs 安慰剂组2.8%,主要见于全剂量方案。

核心结论

  • 在高进展风险的IgA肾病患者中,口服甲泼尼龙治疗6至9个月较安慰剂显著降低肾功能下降、肾衰竭或肾病死亡复合结局的风险。
  • 口服甲泼尼龙增加严重不良事件发生率,主要见于高剂量治疗。

研究设计与样本

  • 国际、多中心、双盲、随机临床试验,纳入503例IgA肾病患者,来自澳大利亚、加拿大、中国、印度和马来西亚的67个中心。
  • 入组条件为经至少3个月优化背景治疗后尿蛋白≥1 g/d且eGFR 20-120 mL/min/1.73 m2,随机化时间为2012年5月至2019年11月,随访至2021年6月。
  • 参与者按1:1随机接受口服甲泼尼龙(初始0.6-0.8 mg/kg/d,最大48 mg/d,每月减量8 mg/d;n=136)或安慰剂(n=126)。
  • 随机化262例后识别出严重感染过多,后续参与者减量(0.4 mg/kg/d,最大32 mg/d,每月减量4 mg/d)并加用抗生素预防肺孢子菌肺炎(甲泼尼龙组121例,安慰剂组120例)。

主要发现

  • 共503例随机化患者(平均年龄38岁;198例[39%]女性;平均eGFR 61.5 mL/min/1.73 m2;平均尿蛋白2.46 g/d),493例(98%)完成试验。
  • 平均随访4.2年,主要结局在甲泼尼龙组74例(28.8%)发生,安慰剂组106例(43.1%)发生(HR 0.53 [95%CI 0.39-0.72];P<.001;绝对年事件率差异-4.8%/年 [95%CI -8.0%至-1.6%])。
  • 各剂量与相应方案安慰剂组比较均见主要结局效应(异质性P=.11):全剂量HR 0.58(95%CI 0.41-0.81);减量HR 0.27(95%CI 0.11-0.65)。
  • 11个预设次要终点中9个显示有利于干预的显著差异,包括肾衰竭(50例[19.5%] vs 67例[27.2%];HR 0.59 [95%CI 0.40-0.87];P=.008;年事件率差异-2.9%/年 [95%CI -5.4%至-0.3%])。
  • 严重不良事件甲泼尼龙组28例(10.9%)vs 安慰剂组7例(2.8%),主要见于全剂量治疗与其匹配安慰剂比较(22例[16.2%] vs 4例[3.2%])。

关键数值与推荐

  • 主要终点为eGFR下降40%、肾衰竭(透析、移植)或肾病死亡的复合终点。
  • 甲泼尼龙组主要终点28.8% vs 安慰剂组43.1%(HR 0.53,95%CI 0.39-0.72;P<.001)。
  • 肾衰竭甲泼尼龙组19.5% vs 安慰剂组27.2%(HR 0.59,95%CI 0.40-0.87;P=.008)。
  • 严重不良事件甲泼尼龙组10.9% vs 安慰剂组2.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. OBJECTIVE: To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function decline. DESIGN, SETTING, AND PARTICIPANTS: An international, multicenter, double-blind, randomized clinical trial that enrolled 503 participants with IgA nephropathy, proteinuria greater than or equal to 1 g per day, and estimated glomerular filtration rate (eGFR) of 20 to 120 mL/min/1.73 m2 after at least 3 months of optimized background care from 67 centers in Australia, Canada, China, India, and Malaysia between May 2012 and November 2019, with follow-up until June 2021. INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive oral methylprednisolone (initially 0.6-0.8 mg/kg/d, maximum 48 mg/d, weaning by 8 mg/d/mo; n = 136) or placebo (n = 126). After 262 participants were randomized, an excess of serious infections was identified, leading to dose reduction (0.4 mg/kg/d, maximum 32 mg/d, weaning by 4 mg/d/mo) and addition of antibiotic prophylaxis for pneumocystis pneumonia for subsequent participants (121 in the oral methylprednisolone group and 120 in the placebo group). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of 40% decline in eGFR, kidney failure (dialysis, transplant), or death due to kidney disease. There were 11 secondary outcomes, including kidney failure. RESULTS: Among 503 randomized patients (mean age, 38 years; 198 [39%] women; mean eGFR, 61.5 mL/min/1.73 m2; mean proteinuria, 2.46 g/d), 493 (98%) completed the trial. Over a mean of 4.2 years of follow-up, the primary outcome occurred in 74 participants (28.8%) in the methylprednisolone group compared with 106 (43.1%) in the placebo group (hazard ratio [HR], 0.53 [95% CI, 0.39-0.72]; P < .001; absolute annual event rate difference, -4.8% per year [95% CI, -8.0% to -1.6%]). The effect on the primary outcome was seen across each dose compared with the relevant participants in the placebo group recruited to each regimen (P for heterogeneity = .11): full-dose HR, 0.58 (95% CI, 0.41-0.81); reduced-dose HR, 0.27 (95% CI, 0.11-0.65). Of the 11 prespecified secondary end points, 9 showed significant differences in favor of the intervention, including kidney failure (50 [19.5%] vs 67 [27.2%]; HR, 0.59 [95% CI, 0.40-0.87]; P = .008; annual event rate difference, -2.9% per year [95% CI, -5.4% to -0.3%]). Serious adverse events were more frequent with methylprednisolone vs placebo (28 [10.9%] vs 7 [2.8%] patients with serious adverse events), primarily with full-dose therapy compared with its matching placebo (22 [16.2%] vs 4 [3.2%]). CONCLUSIONS AND RELEVANCE: Among patients with IgA nephropathy at high risk of progression, treatment with oral methylprednisolone for 6 to 9 months, compared with placebo, significantly reduced the risk of the composite outcome of kidney function decline, kidney failure, or death due to kidney disease. However, the incidence of serious adverse events was increased with oral methylprednisolone, mainly with high-dose therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01560052.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lv J, Wong MG, Hladunewich MA, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022. PMID: 35579642. doi:10.1001/jama.2022.5368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。